补肺化瘀汤联合化疗治疗非小细胞肺癌的临床观察

摘要

目的:观察补肺化瘀汤联合化疗治疗非小细胞肺癌(NSCLC)的临床疗效、安全性及其对血管内皮生长因子(VEGF)及免疫功能的影响.方法:选取2013年10月-2015年6月在我院接受治疗的NSCLC患者120例作为研究对象,按随机数字表法分为观察组和对照组,各60例.对照组患者给予GP(吉西他滨+顺铂)方案化疗,观察组患者在对照组基础上加用补肺化瘀汤,每日1剂,水煎取汁400 mL,分早晚2次温服.比较两组患者临床疗效及治疗前后血清VEGF-A、VEGF-B、VEGF-C和免疫指标(CD3+、CD4+、CD8+、CD4+/CD8+)水平,并记录毒副反应发生情况.结果:观察组患者的临床有效率、疾病控制率分别为58.33％、85.00％,显著高于对照组的40.00％、68.33％,差异均有统计学意义(P0.05).治疗后,两组患者血清VEGF水平均显著降低,且观察组显著低于对照组,差异均有统计学意义(P0.05). After treatment,VEGF of 2 groups were decreased significantly,and observation group was significantly lower than the con-trol group,with statistical significance(P<0.05);CD4+and CD4+/CD8+of 2 groups were decreased significantly,while CD8+was increased significantly,with statistical significance(P<0.05);CD4+ and CD4+/CD8+ of observation group were significantly higher than those of control group,while CD8+ was decreased significantly;CD3+ of control group was decreased significantly and lower than observation group,with statistical significance (P<0.05). The incidence of leucopenia,thrombocytopenia,decrease of hemo-globin,elevation of transaminase,increase of bilirubin and digestive tract reaction in observation group was significantly lower than control group,with statistical significance(P<0.05). CONCLUSIONS:Bufei huayu decoction combined with chemotherapy shows significant therapeutic efficacy for NSCLC,can effectively inhibit VEGF,improve immune function and relieve toxic reaction.